Ligands that recognize the amyloid-β (Aβ) oligomers implicated in Alzheimer disease could be useful for diagnostic and therapeutic applications. However, discovering such binders is challenging because of the difficulty of measuring oligomer-binding activity. A strategy has now been reported to detect binding to Aβ42 oligomers, which is used to select new binders with improved potency.
- ByungUk Lee
- John A. Mannone
- Tina Wang
